Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar
Authors:
Preprint
Abstract
BACKGROUND: The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022. METHODS: Three national, matched, retrospective cohort studies were conducted to compare incidence of SARS-CoV-2 infection and COVID-19 severity among unvaccinated persons with a documented SARS-CoV-2 primary infection, to incidence among those infection-naïve and unvaccinated. Associations were estimated using Cox proportional-hazard regression models. RESULTS: Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection was 85.5% (95% CI: 84.8-86.2%). Effectiveness peaked at 90.5% (95% CI: 88.4-92.3%) in the 7 th month after the primary infection, but waned to ∼70% by the 16 th month. Extrapolating this waning trend using a Gompertz curve suggested an effectiveness of 50% in the 22 nd month and nd month. Effectiveness of pre-Omicron primary infection against Omicron reinfection was 38.1% (95% CI: 36.3-39.8%) and declined with time since primary infection. A Gompertz curve suggested an effectiveness of th month. Effectiveness of primary infection against severe, critical, or fatal COVID-19 reinfection was 97.3% (95% CI: 94.9- 98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning. Similar results were found in sub-group analyses for those ≥50 years of age. CONCLUSIONS: Protection of natural infection against reinfection wanes and may diminish within a few years. Viral immune evasion accelerates this waning. Protection against severe reinfection remains very strong, with no evidence for waning, irrespective of variant, for over 14 months after primary infection.Keywords
All Related Versions
- Published version: Journal of Travel Medicine, 29 (8).
This publication has 42 references indexed in Scilit:
- Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two monthsInfection, Genetics and Evolution, 2021
- Immunological characteristics govern the transition of COVID-19 to endemicityScience, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure SettingClinical Infectious Diseases, 2020
- Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic periodScience, 2020
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.American Journal of Epidemiology, 2016
- Longevity and Determinants of Protective Humoral Immunity After Pandemic Influenza InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2015
- The eradication of smallpox – An overview of the past, present, and futureVaccine, 2011
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryNew England Journal of Medicine, 2007
- Still Protected Against Smallpox?Epidemiology, 2006